SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

Qiao, T.Y. and Wang, X.S. (2012) Advances in Diagnosis and Treatment of Liver Metastasis of Colorectal Cancer. Chinese Cancer Clinical and Rehabilitation, 19, 572-575.

has been cited by the following article:

  • TITLE: Clinical Observation of Neoadjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Report of 24 Cases

    AUTHORS: Anxin Wang, Jinjun Li

    KEYWORDS: Neoadjuvant Chemotherapy, Adjuvant Chemotherapy, Colon Cancer, Efficacy, Risk Factors

    JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.13, December 14, 2017

    ABSTRACT: Background: Neoadjuvant chemotherapy is the systemic chemotherapy before the start of local chemotherapy or radiotherapy. At present, neoadjuvant chemotherapy in the high-risk phase II (AJCC TNM stage II period, including T3N0M0 and T4N0M0) treatment of colon cancer reported less. The authors discussed the efficacy and safety of neoadjuvant chemotherapy in 24 patients with high-risk stage II colorectal cancer. Method: Forty-eight patients with stage II colorectal cancer were randomly divided into experimental group and control group, the postoperative complications, the side effects of chemotherapy drugs and the effect of chemotherapy drugs on the tumor were observed. The quality of life, survival time and tumor recurrence or metastasis was compared between the two groups. Result: 1) The incidence of complications in the neoadjuvant chemotherapy group was 20.8%, the incidence of adjuvant chemotherapy was 25%, and the overall complication rate was 22.9%. P values were greater than 0.05. 2) Through the comparison of the two groups of toxic and side effects, after SPASS software analysis, obtained P > 0.05, the two groups were not statistically significant. 3) After 3 - 4 courses of preoperative chemotherapy, CR (complete remission) and PD (disease progression) patients were 0 cases, PR (partial remission) was 11 (45.8%), NC/SD (no change) was 13 (54.2%). 4) Through the comparison of the quality of life of the two groups of patients, from the function, symptoms and the overall situation to statistics, P value 0.05, This comparison makes sense. 5) The 1-year survival rate was 100% (24/24) in the control group, with a 3-year survival rate of 92% (22/24) and a 5-year survival rate of 75% (9/12). All survival rates in the experimental group were 100% (24/24). 6) There were no recurrence or metastasis cases in the neoadjuvant chemotherapy group, and 2 cases of recurrence and 1 case of metastasis in the adjuvant chemotherapy group were compared with the recurrence or metastasis after tumor operation. The chi-square test is not statistically significant. Conclusion: Neoadjuvant chemotherapy plays a role in patients with high-risk second-stage colon cancer, the experimental group benefited significantly, especially in quality of life and survival time. At the same time, neoadjuvant chemotherapy is also a safe treatment.